About United Therapeutics (NASDAQ:UTHR)
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292
Debt
Debt-to-Equity Ratio0.12%
Current Ratio3.26%
Quick Ratio3.01%
Price-To-Earnings
Trailing P/E Ratio10.47
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.73 billion
Price / Sales2.86
Cash Flow$12.0316 per share
Price / Cash9.48
Book Value$48.64 per share
Price / Book2.34
Profitability
EPS (Most Recent Fiscal Year)$10.89
Net Income$417.90 million
Net Margins24.22%
Return on Equity24.41%
Return on Assets17.67%
Miscellaneous
Employees800
Outstanding Shares43,240,000
United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions
What is United Therapeutics' stock symbol?
United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."
How will United Therapeutics' stock buyback program work?
United Therapeutics announced that its Board of Directors has approved a stock buyback plan on Sunday, June 4th 2017, which permits the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 4.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.
How were United Therapeutics' earnings last quarter?
United Therapeutics Co. (NASDAQ:UTHR) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported $3.89 EPS for the quarter, topping analysts' consensus estimates of $3.59 by $0.30. The biotechnology company earned $464.70 million during the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The business's revenue was up 13.6% compared to the same quarter last year. During the same period last year, the firm earned $4.12 earnings per share. View United Therapeutics' Earnings History.
When is United Therapeutics' next earnings date?
What price target have analysts set for UTHR?
8 Wall Street analysts have issued twelve-month target prices for United Therapeutics' shares. Their predictions range from $95.00 to $232.00. On average, they expect United Therapeutics' stock price to reach $133.3750 in the next year. View Analyst Ratings for United Therapeutics.
What are Wall Street analysts saying about United Therapeutics stock?
Here are some recent quotes from research analysts about United Therapeutics stock:
- 1. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company, at present, has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Several data read-outs and regulatory updates are expected in 2018. However, increased competitive pressure from Uptravi on its PAH drugs, mainly Orenitram, is a concern. We believe the company needs to use cash suitably to deal with generic competition for Remodulin that could materialize post Jun 2018. However, United Therapeutics’ shares have outperformed the industry in the past six months. Estimates have gone up ahead of the Q4 earnings release. The company has a mixed record of earnings surprises in the recent quarters. " (1/15/2018)
- 2. Cowen Inc analysts commented, "1Q Revenues were weak across the prostacyclin PAH franchise." (4/26/2017)
Who are some of United Therapeutics' key competitors?
Some companies that are related to United Therapeutics include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH) and Advanced Accelerator Application (AAAP).
Who are United Therapeutics' key executives?
United Therapeutics' management team includes the folowing people:
- Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
- Mr. Michael I. Benkowitz, Pres & COO (Age 46)
- Mr. James C. Edgemond, CFO & Treasurer (Age 50)
- Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Kevin Gray, Sr. VP of Strategic Operations & Logistics
Has United Therapeutics been receiving favorable news coverage?
News coverage about UTHR stock has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. United Therapeutics earned a news impact score of 0.05 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of United Therapeutics?
Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is United Therapeutics' stock price today?
One share of UTHR stock can currently be purchased for approximately $114.06.
How big of a company is United Therapeutics?
United Therapeutics has a market capitalization of $4.93 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.
How can I contact United Therapeutics?
United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]
MarketBeat Community Rating for United Therapeutics (UTHR)
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
United Therapeutics (NASDAQ:UTHR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for United Therapeutics in the last 12 months. Their average twelve-month price target is $133.3750, suggesting that the stock has a possible upside of 16.93%. The high price target for UTHR is $232.00 and the low price target for UTHR is $95.00. There are currently 3 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 1.88 | 1.78 | 1.90 | 1.83 |
| Ratings Breakdown: | 3 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 4 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 4 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $133.3750 | $132.4444 | $138.30 | $132.0909 |
| Price Target Upside: | 16.93% upside | 8.41% upside | 1.16% downside | 9.33% upside |
United Therapeutics (NASDAQ:UTHR) Consensus Price Target History
United Therapeutics (NASDAQ:UTHR) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
United Therapeutics (NASDAQ:UTHR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
United Therapeutics (NASDAQ UTHR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.80%
United Therapeutics (NASDAQ UTHR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Martine A Rothblatt | CEO | Sell | 21,513 | $110.88 | $2,385,361.44 | 21,653 |  |
| 4/5/2018 | Martine A Rothblatt | CEO | Sell | 21,512 | $114.30 | $2,458,821.60 | 21,652 | |
| 4/3/2018 | Martine A Rothblatt | CEO | Sell | 22,059 | $114.44 | $2,524,431.96 | 687 | |
| 3/29/2018 | Martine A Rothblatt | CEO | Sell | 43,024 | $111.14 | $4,781,687.36 | 21,652 | |
| 3/22/2018 | Martine A Rothblatt | CEO | Sell | 1,100 | $110.01 | $121,011.00 | 1,240 | |
| 3/20/2018 | Martine A Rothblatt | CEO | Sell | 301 | $110.48 | $33,254.48 | 21,652 | |
| 3/16/2018 | Martine A Rothblatt | CEO | Sell | 43,025 | $111.11 | $4,780,507.75 | 21,652 | |
| 3/14/2018 | Martine A Rothblatt | CEO | Sell | 21,512 | $112.55 | $2,421,175.60 | 21,652 | |
| 12/8/2017 | Martine A Rothblatt | CEO | Sell | 1 | $136.16 | $136.16 | 141 | |
| 12/7/2017 | Christopher Causey | Director | Sell | 580 | $134.72 | $78,137.60 | 1,555 | |
| 11/30/2017 | Martine A Rothblatt | CEO | Sell | 1,241 | $128.95 | $160,026.95 | | |
| 11/24/2017 | Martine A Rothblatt | CEO | Sell | 1,253 | $124.07 | $155,459.71 | | |
| 11/16/2017 | Martine A Rothblatt | CEO | Sell | 7,061 | $121.12 | $855,228.32 | | |
| 11/9/2017 | Martine A Rothblatt | CEO | Sell | 1,260 | $121.46 | $153,039.60 | 1,400 | |
| 11/6/2017 | Christopher Causey | Director | Sell | 580 | $122.00 | $70,760.00 | 2,135 | |
| 11/2/2017 | Martine A Rothblatt | CEO | Sell | 1,269 | $118.04 | $149,792.76 | 1,409 | |
| 10/26/2017 | Martine A Rothblatt | CEO | Sell | 1,263 | $120.38 | $152,039.94 | 1,403 | |
| 10/19/2017 | Martine A Rothblatt | CEO | Sell | 1,265 | $119.38 | $151,015.70 | 1,405 | |
| 10/12/2017 | Martine A Rothblatt | CEO | Sell | 1,263 | $120.20 | $151,812.60 | | |
| 10/5/2017 | Christopher Causey | Director | Sell | 580 | $122.00 | $70,760.00 | | |
| 10/5/2017 | Martine A Rothblatt | CEO | Sell | 1,256 | $122.98 | $154,462.88 | | |
| 9/28/2017 | Martine A Rothblatt | CEO | Sell | 1,265 | $119.70 | $151,420.50 | 2,334 | |
| 9/21/2017 | Martine A Rothblatt | CEO | Sell | 1,274 | $116.07 | $147,873.18 | 2,343 | |
| 9/14/2017 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.08 | $153,576.64 | 2,327 | |
| 9/7/2017 | Christopher Causey | Director | Sell | 580 | $134.48 | $77,998.40 | 3,295 | |
| 9/7/2017 | Martine A Rothblatt | CEO | Sell | 1,232 | $133.32 | $164,250.24 | 2,301 | |
| 8/31/2017 | Martine A Rothblatt | CEO | Sell | 1,235 | $130.49 | $161,155.15 | 2,304 | |
| 8/24/2017 | Martine A Rothblatt | CEO | Sell | 1,238 | $130.65 | $161,744.70 | 2,307 | |
| 8/17/2017 | Martine A Rothblatt | CEO | Sell | 1,235 | $131.95 | $162,958.25 | 2,304 | |
| 8/10/2017 | Martine A Rothblatt | CEO | Sell | 2,176 | $127.11 | $276,591.36 | 3,245 | |
| 8/3/2017 | Martine A Rothblatt | CEO | Sell | 1,248 | $126.41 | $157,759.68 | 2,317 | |
| 7/27/2017 | Martine A Rothblatt | CEO | Sell | 1,247 | $126.40 | $157,620.80 | 2,316 | |
| 7/20/2017 | Martine A Rothblatt | CEO | Sell | 1,236 | $131.62 | $162,682.32 | 1,376 | |
| 7/13/2017 | Martine A Rothblatt | CEO | Sell | 1,238 | $130.44 | $161,484.72 | 1,378 | |
| 7/6/2017 | Christopher Causey | Director | Sell | 590 | $132.61 | $78,239.90 | 3,875 | |
| 7/6/2017 | Martine A Rothblatt | CEO | Sell | 1,234 | $132.29 | $163,245.86 | 1,374 | |
| 7/5/2017 | Richard Giltner | Director | Sell | 3,490 | $131.12 | $457,608.80 | | |
| 6/29/2017 | Martine A Rothblatt | CEO | Sell | 1,237 | $130.92 | $161,948.04 | 1,377 | |
| 6/23/2017 | Raymond Dwek | Director | Sell | 3,490 | $131.71 | $459,667.90 | | |
| 6/22/2017 | Martine A Rothblatt | CEO | Sell | 1,234 | $132.32 | $163,282.88 | 1,374 | |
| 6/15/2017 | Martine A Rothblatt | CEO | Sell | 1,238 | $130.20 | $161,187.60 | 1,378 | |
| 6/8/2017 | Martine A Rothblatt | CEO | Sell | 1,240 | $129.60 | $160,704.00 | 1,380 | |
| 6/1/2017 | Martine A Rothblatt | CEO | Sell | 1,251 | $125.02 | $156,400.02 | 1,391 | |
| 5/25/2017 | Martine A Rothblatt | CEO | Sell | 1,265 | $119.40 | $151,041.00 | 1,405 | |
| 5/18/2017 | Martine A Rothblatt | CEO | Sell | 1,261 | $120.72 | $152,227.92 | 1,401 | |
| 5/11/2017 | Martine A Rothblatt | CEO | Sell | 1,259 | $122.00 | $153,598.00 | 1,399 | |
| 5/4/2017 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.24 | $153,777.92 | 1,398 | |
| 4/27/2017 | Martine A Rothblatt | CEO | Sell | 1,262 | $120.78 | $152,424.36 | 1,402 | |
| 4/20/2017 | Martine A Rothblatt | CEO | Sell | 1,260 | $121.14 | $152,636.40 | 1,400 | |
| 4/13/2017 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.12 | $153,626.96 | 1,398 | |
| 4/6/2017 | Martine A Rothblatt | CEO | Sell | 1,257 | $122.39 | $153,844.23 | 1,397 | |
| 3/30/2017 | Martine A Rothblatt | CEO | Sell | 1,230 | $134.56 | $165,508.80 | 1,370 | |
| 3/23/2017 | Martine A Rothblatt | CEO | Sell | 1,219 | $139.33 | $169,843.27 | 1,359 | |
| 3/22/2017 | Tommy G Thompson | Director | Sell | 2,000 | $139.37 | $278,740.00 | 2,000 | |
| 3/16/2017 | Martine A Rothblatt | CEO | Sell | 1,218 | $140.16 | $170,714.88 | 1,358 | |
| 3/9/2017 | Martine A Rothblatt | CEO | Sell | 1,206 | $146.72 | $176,944.32 | 1,346 | |
| 3/2/2017 | Martine A Rothblatt | CEO | Sell | 1,203 | $148.49 | $178,633.47 | 1,343 | |
| 2/23/2017 | Martine A Rothblatt | CEO | Sell | 1,208 | $145.16 | $175,353.28 | 1,348 | |
| 2/16/2017 | Martine A Rothblatt | CEO | Sell | 1,173 | $167.92 | $196,970.16 | 1,313 | |
| 1/12/2017 | Christopher Patusky | Director | Sell | 5,000 | $141.99 | $709,950.00 | 5,000 | |
| 1/12/2017 | Martine A Rothblatt | CEO | Sell | 1,214 | $142.37 | $172,837.18 | 1,354 | |
| 1/5/2017 | Martine A Rothblatt | CEO | Sell | 1,208 | $145.73 | $176,041.84 | 1,348 | |
| 12/29/2016 | Martine A Rothblatt | CEO | Sell | 1,211 | $143.63 | $173,935.93 | 1,351 | |
| 12/22/2016 | Martine A Rothblatt | CEO | Sell | 1,218 | $140.23 | $170,800.14 | 1,358 | |
| 12/15/2016 | Martine A Rothblatt | CEO | Sell | 1,212 | $143.11 | $173,449.32 | 1,352 | |
| 12/8/2016 | Martine A Rothblatt | CEO | Sell | 1,236 | $131.78 | $162,880.08 | 1,376 | |
| 12/6/2016 | Richard Giltner | Director | Sell | 5,000 | $133.37 | $666,850.00 | 5,000 | |
| 12/1/2016 | Martine A Rothblatt | CEO | Sell | 1,246 | $126.86 | $158,067.56 | 1,386 | |
| 11/25/2016 | Martine A Rothblatt | CEO | Sell | 1,233 | $132.81 | $163,754.73 | 1,373 | |
| 11/17/2016 | Martine A Rothblatt | CEO | Sell | 1,232 | $132.94 | $163,782.08 | 1,372 | |
| 11/10/2016 | Christopher Patusky | Director | Sell | 5,000 | $131.42 | $657,100.00 | 5,000 | |
| 11/10/2016 | Martine A Rothblatt | CEO | Sell | 1,240 | $129.82 | $160,976.80 | 1,380 | |
| 11/3/2016 | Martine A Rothblatt | CEO | Sell | 1,272 | $116.94 | $148,747.68 | 1,412 | |
| 10/27/2016 | Martine A Rothblatt | CEO | Sell | 1,272 | $117.06 | $148,900.32 | 1,412 | |
| 10/20/2016 | Martine A Rothblatt | CEO | Sell | 1,282 | $113.30 | $145,250.60 | 1,422 | |
| 10/13/2016 | Martine A Rothblatt | CEO | Sell | 1,269 | $117.99 | $149,729.31 | 1,409 | |
| 10/6/2016 | Martine A Rothblatt | CEO | Sell | 1,260 | $121.17 | $152,674.20 | 1,400 | |
| 9/29/2016 | Martine A Rothblatt | CEO | Sell | 1,272 | $116.94 | $148,747.68 | 1,412 | |
| 9/26/2016 | Tommy G Thompson | Director | Sell | 1,291 | $125.57 | $162,110.87 | 1,291 | |
| 9/22/2016 | Martine A Rothblatt | CEO | Sell | 1,249 | $125.87 | $157,211.63 | 1,389 | |
| 9/15/2016 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.34 | $153,903.72 | 1,398 | |
| 9/8/2016 | Martine A Rothblatt | CEO | Sell | 1,254 | $123.44 | $154,793.76 | 1,394 | |
| 9/1/2016 | Christopher Patusky | Director | Sell | 5,000 | $122.73 | $613,650.00 | 5,000 | |
| 9/1/2016 | Martine A Rothblatt | CEO | Sell | 1,257 | $122.81 | $154,372.17 | 1,397 | |
| 8/25/2016 | Martine A Rothblatt | CEO | Sell | 1,250 | $125.29 | $156,612.50 | 1,390 | |
| 8/18/2016 | Martine A Rothblatt | CEO | Sell | 1,249 | $125.88 | $157,224.12 | 1,389 | |
| 8/11/2016 | Martine A Rothblatt | CEO | Sell | 1,253 | $124.09 | $155,484.77 | 1,393 | |
| 8/4/2016 | Martine A Rothblatt | CEO | Sell | 1,249 | $125.78 | $157,099.22 | 1,389 | |
| 7/28/2016 | Martine A Rothblatt | CEO | Sell | 1,271 | $117.05 | $148,770.55 | 1,411 | |
| 7/21/2016 | Martine A Rothblatt | CEO | Sell | 1,284 | $112.77 | $144,796.68 | 1,424 | |
| 7/14/2016 | Martine A Rothblatt | CEO | Sell | 1,292 | $110.05 | $142,184.60 | 1,432 | |
| 7/7/2016 | Martine A Rothblatt | CEO | Sell | 1,293 | $109.87 | $142,061.91 | 1,433 | |
| 6/30/2016 | Martine A Rothblatt | CEO | Sell | 1,308 | $105.10 | $137,470.80 | 1,548 | |
| 6/23/2016 | Martine A Rothblatt | CEO | Sell | 1,312 | $104.07 | $136,539.84 | 1,552 | |
| 6/16/2016 | Martine A Rothblatt | CEO | Sell | 1,308 | $105.18 | $137,575.44 | 1,548 | |
| 6/9/2016 | Martine A Rothblatt | CEO | Sell | 1,277 | $114.99 | $146,842.23 | 1,517 | |
| 6/8/2016 | Tommy G Thompson | Director | Sell | 2,000 | $115.62 | $231,240.00 | 2,000 | |
| 6/2/2016 | Martine A Rothblatt | CEO | Sell | 1,261 | $120.79 | $152,316.19 | 1,501 | |
| 6/2/2016 | Raymond Dwek | Director | Sell | 3,000 | $118.82 | $356,460.00 | 3,000 | |
| 5/26/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $117.57 | $652,160.79 | 5,787 | |
| 5/19/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $110.75 | $614,219.50 | 5,786 | |
| 5/12/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $109.02 | $604,733.94 | 5,787 | |
| 5/12/2016 | Raymond Dwek | Director | Sell | 3,000 | $110.00 | $330,000.00 | 3,000 | |
| 5/5/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $107.79 | $597,803.34 | 5,786 | |
| 4/28/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $106.81 | $592,475.07 | 5,787 | |
| 4/21/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $115.74 | $641,894.04 | 5,786 | |
| 4/14/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $114.32 | $634,133.04 | 5,787 | |
| 4/7/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $113.31 | $628,417.26 | 5,786 | |
| 3/24/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $110.80 | $614,496.80 | 5,786 | |
| 3/17/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $118.22 | $655,766.34 | 5,787 | |
| 3/10/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $123.41 | $684,431.86 | 5,786 | |
| 3/3/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $126.78 | $703,248.66 | 5,787 | |
| 2/25/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $122.45 | $679,107.70 | 5,786 | |
| 2/18/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $128.26 | $711,458.22 | 5,787 | |
| 2/11/2016 | Martine A. Rothblatt | CEO | Sell | 5,546 | $120.47 | $668,126.62 | 240 | |
| 2/4/2016 | Martine A. Rothblatt | CEO | Sell | 5,547 | $122.13 | $677,455.11 | 240 | |
| 2/4/2016 | Raymond Dwek | Director | Sell | 3,000 | $122.66 | $367,980.00 | | |
| 1/28/2016 | Martine A. Rothblatt | CEO | Sell | 5,546 | $124.00 | $687,704.00 | 240 | |
| 1/21/2016 | Martine A. Rothblatt | CEO | Sell | 5,547 | $127.00 | $704,469.00 | 240 | |
| 1/14/2016 | Martine A. Rothblatt | CEO | Sell | 5,546 | $135.94 | $753,923.24 | 240 | |
| 1/7/2016 | Martine A. Rothblatt | CEO | Sell | 5,547 | $145.84 | $808,974.48 | 240 | |
| 1/7/2016 | Raymond Dwek | Director | Sell | 3,000 | $143.75 | $431,250.00 | | |
| 12/24/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $159.58 | $885,030.68 | 240 | |
| 12/17/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $158.49 | $878,985.54 | 240 | |
| 12/10/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $154.49 | $856,801.54 | 240 | |
| 12/3/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $154.49 | $856,801.54 | 240 | |
| 12/3/2015 | Raymond Dwek | Director | Sell | 3,000 | $157.22 | $471,660.00 | | |
| 11/27/2015 | Martine A. Rothblatt | CEO | Sell | 5,561 | $153.81 | $855,337.41 | 240 | |
| 11/19/2015 | Martine A. Rothblatt | CEO | Sell | 9,661 | $148.56 | $1,435,238.16 | 240 | |
| 11/12/2015 | Martine A. Rothblatt | CEO | Sell | 4,115 | $147.72 | $607,867.80 | 240 | |
| 11/5/2015 | Martine A. Rothblatt | CEO | Sell | 4,115 | $149.16 | $613,793.40 | 240 | |
| 11/5/2015 | Raymond Dwek | Director | Sell | 3,000 | $149.63 | $448,890.00 | | |
| 11/3/2015 | Richard Giltner | Director | Sell | 7,500 | $153.22 | $1,149,150.00 | | |
| 10/29/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $141.89 | $1,370,941.18 | 240 | |
| 10/28/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $136.58 | $301,978.38 | 240 | |
| 10/26/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $127.13 | $329,520.96 | 240 | |
| 10/22/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $122.40 | $1,182,628.80 | 240 | |
| 10/21/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $123.63 | $273,345.93 | 240 | |
| 10/19/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $126.71 | $328,432.32 | 240 | |
| 10/15/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $126.22 | $1,219,537.64 | 240 | |
| 10/14/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $123.53 | $273,124.83 | 240 | |
| 10/12/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $123.51 | $320,137.92 | 240 | |
| 10/8/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $122.48 | $1,183,401.76 | 240 | |
| 10/7/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $120.88 | $267,265.68 | 240 | |
| 10/5/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $126.88 | $328,872.96 | 240 | |
| 10/1/2015 | Martine A. Rothblatt | CEO | Sell | 6,326 | $131.11 | $829,401.86 | 240 | |
| 10/1/2015 | Paul A. Mahon | EVP | Sell | 6,000 | $129.38 | $776,280.00 | 35,054 | |
| 10/1/2015 | Raymond Dwek | Director | Sell | 3,000 | $131.32 | $393,960.00 | | |
| 9/29/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $134.25 | $347,976.00 | 240 | |
| 9/29/2015 | Tommy G. Thompson | Director | Sell | 5,000 | $139.19 | $695,950.00 | | |
| 9/24/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $139.26 | $1,345,530.12 | 240 | |
| 9/23/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $142.05 | $314,072.55 | 240 | |
| 9/21/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $150.81 | $390,899.52 | 240 | |
| 9/17/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $152.02 | $1,468,817.24 | 240 | |
| 9/16/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $151.93 | $335,917.23 | 240 | |
| 9/14/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $153.08 | $396,783.36 | 240 | |
| 9/10/2015 | Martine A. Rothblatt | CEO | Sell | 4,115 | $152.95 | $629,389.25 | 240 | |
| 9/9/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $152.77 | $337,774.47 | 240 | |
| 9/8/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $152.80 | $396,057.60 | 240 | |
| 9/3/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $153.67 | $1,484,759.54 | 240 | |
| 9/3/2015 | Raymond Dwek | Director | Sell | 3,000 | $155.54 | $466,620.00 | | |
| 9/2/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $151.12 | $334,126.32 | 240 | |
| 8/31/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $153.50 | $397,872.00 | 240 | |
| 8/27/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $160.37 | $1,549,494.94 | 240 | |
| 8/26/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $155.47 | $343,744.17 | 240 | |
| 8/24/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $155.36 | $402,693.12 | 240 | |
| 8/20/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $166.58 | $1,609,495.96 | 240 | |
| 8/19/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $167.13 | $369,524.43 | 240 | |
| 8/17/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $166.61 | $431,853.12 | | |
| 8/13/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $165.05 | $1,594,713.10 | | |
| 7/27/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $166.38 | $431,256.96 | | |
| 7/23/2015 | Martine A Rothblatt | CEO | Sell | 4,115 | $176.38 | $725,803.70 | | |
| 7/22/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $174.55 | $385,930.05 | | |
| 7/20/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.92 | $461,168.64 | | |
| 7/16/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $175.51 | $1,695,777.62 | | |
| 7/15/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $176.77 | $390,838.47 | | |
| 7/13/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $172.42 | $446,912.64 | | |
| 7/9/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $168.04 | $1,623,602.48 | | |
| 7/8/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $167.13 | $369,524.43 | | |
| 7/6/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $170.66 | $442,350.72 | | |
| 7/2/2015 | Martine A Rothblatt | CEO | Sell | 6,326 | $170.69 | $1,079,784.94 | | |
| 7/2/2015 | Raymond Dwek | Director | Sell | 3,000 | $171.59 | $514,770.00 | | |
| 6/29/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $172.86 | $448,053.12 | | |
| 6/25/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $176.91 | $1,709,304.42 | | |
| 6/24/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $179.68 | $397,272.48 | | |
| 6/22/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $188.64 | $488,954.88 | | |
| 6/18/2015 | Louis W Sullivan | Director | Sell | 15,000 | $185.60 | $2,784,000.00 | | |
| 6/18/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $185.72 | $1,794,426.64 | | |
| 6/17/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $185.25 | $409,587.75 | | |
| 6/15/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $185.15 | $479,908.80 | | |
| 6/11/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $183.76 | $1,775,489.12 | | |
| 6/10/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $180.87 | $399,903.57 | | |
| 6/8/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $181.34 | $470,033.28 | | |
| 6/4/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $181.94 | $1,757,904.28 | | |
| 6/4/2015 | Raymond Dwek | Director | Sell | 3,000 | $181.36 | $544,080.00 | | |
| 6/3/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $184.49 | $407,907.39 | | |
| 6/1/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $182.66 | $473,454.72 | | |
| 5/28/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $180.88 | $1,747,662.56 | | |
| 5/27/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $184.39 | $407,686.29 | | |
| 5/26/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $182.64 | $473,402.88 | | |
| 5/21/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $182.44 | $1,762,735.28 | | |
| 5/21/2015 | Tommy G Thompson | Director | Sell | 1,500 | $182.04 | $273,060.00 | | |
| 5/20/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $182.80 | $404,170.80 | | |
| 5/18/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.79 | $460,831.68 | | |
| 5/14/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $174.07 | $1,681,864.34 | | |
| 5/13/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $175.41 | $387,831.51 | | |
| 5/11/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $179.55 | $465,393.60 | | |
| 5/7/2015 | Christopher Causey | Director | Sell | 1,500 | $167.94 | $251,910.00 | | |
| 5/7/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $169.86 | $1,641,187.32 | | |
| 5/6/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $169.22 | $374,145.42 | | |
| 5/4/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $169.81 | $440,147.52 | | |
| 5/1/2015 | Raymond Dwek | Director | Sell | 3,000 | $159.58 | $478,740.00 | | |
| 4/30/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $162.36 | $1,568,722.32 | | |
| 4/29/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $164.29 | $363,245.19 | | |
| 4/28/2015 | Roger Jeffs | CEO | Sell | 5,000 | $163.31 | $816,550.00 | | |
| 4/27/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.62 | $460,391.04 | | |
| 4/23/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $187.35 | $1,810,175.70 | | |
| 4/22/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $187.49 | $414,540.39 | | |
| 4/21/2015 | Roger Jeffs | CEO | Sell | 10,000 | $187.86 | $1,878,600.00 | | |
| 4/20/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $184.86 | $479,157.12 | | |
| 4/16/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $187.01 | $2,220,369.73 | | |
| 4/16/2015 | Paul A Mahon | EVP | Sell | 6,000 | $187.91 | $1,127,460.00 | | |
| 4/14/2015 | David Zaccardelli | COO | Sell | 3,250 | $185.82 | $603,915.00 | | |
| 4/14/2015 | Roger Jeffs | CEO | Sell | 10,000 | $185.82 | $1,858,200.00 | | |
| 4/13/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $187.86 | $486,933.12 | | |
| 4/9/2015 | David Zaccardelli | COO | Sell | 4,000 | $184.84 | $739,360.00 | | |
| 4/9/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $183.09 | $1,769,015.58 | | |
| 4/8/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $181.91 | $402,203.01 | | |
| 4/7/2015 | David Zaccardelli | COO | Sell | 4,000 | $179.34 | $717,360.00 | | |
| 4/7/2015 | Roger Jeffs | CEO | Sell | 10,000 | $179.34 | $1,793,400.00 | | |
| 4/6/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $176.20 | $456,710.40 | | |
| 4/2/2015 | David Zaccardelli | COO | Sell | 4,000 | $174.73 | $698,920.00 | | |
| 4/2/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $173.43 | $2,059,134.39 | | |
| 4/2/2015 | Paul A Mahon | EVP | Sell | 6,000 | $174.73 | $1,048,380.00 | | |
| 4/2/2015 | Raymond Dwek | Director | Sell | 3,000 | $175.49 | $526,470.00 | | |
| 3/30/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.22 | $459,354.24 | | |
| 3/26/2015 | David Zaccardelli | COO | Sell | 4,000 | $167.52 | $670,080.00 | | |
| 3/26/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $167.03 | $1,613,843.86 | | |
| 3/25/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $173.67 | $383,984.37 | | |
| 3/24/2015 | David Zaccardelli | COO | Sell | 4,500 | $179.51 | $807,795.00 | | |
| 3/23/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.76 | $460,753.92 | | |
| 3/19/2015 | Paul A Mahon | EVP | Sell | 6,000 | $175.82 | $1,054,920.00 | | |
| 3/18/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $174.64 | $386,129.04 | | |
| 3/17/2015 | David Zaccardelli | COO | Sell | 4,000 | $177.34 | $709,360.00 | | |
| 3/16/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $170.97 | $443,154.24 | | |
| 3/12/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $162.94 | $1,934,586.62 | | |
| 3/10/2015 | Roger Jeffs | CEO | Sell | 18,750 | $143.68 | $2,694,000.00 | | |
| 3/9/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $160.51 | $416,041.92 | | |
| 3/5/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $159.75 | $1,543,504.50 | | |
| 3/5/2015 | Raymond Dwek | Director | Sell | 3,000 | $157.59 | $472,770.00 | | |
| 3/4/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $157.63 | $348,519.93 | | |
| 3/3/2015 | Roger Jeffs | CEO | Sell | 10,000 | $157.74 | $1,577,400.00 | | |
| 3/2/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $155.32 | $402,589.44 | | |
| 2/27/2015 | Ray Kurzweil | Director | Sell | 15,000 | $155.05 | $2,325,750.00 | | |
| 2/26/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $155.23 | $1,499,832.26 | | |
| 2/25/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $159.35 | $352,322.85 | | |
| 2/24/2015 | David Zaccardelli | COO | Sell | 1,458 | $155.16 | $226,223.28 | | |
| 2/24/2015 | Roger Jeffs | CEO | Sell | 10,000 | $155.16 | $1,551,600.00 | | |
| 2/23/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $156.08 | $404,559.36 | | |
| 2/19/2015 | John Maxim Ferrari | CFO | Sell | 10,000 | $155.72 | $1,557,200.00 | | |
| 2/19/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $155.99 | $1,507,175.38 | | |
| 2/19/2015 | Paul A Mahon | EVP | Sell | 6,000 | $155.72 | $934,320.00 | | |
| 2/17/2015 | David Zaccardelli | COO | Sell | 4,000 | $155.14 | $620,560.00 | | |
| 2/17/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $152.28 | $394,709.76 | | |
| 2/12/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $146.01 | $1,410,748.62 | | |
| 2/11/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $147.29 | $325,658.19 | | |
| 2/10/2015 | David Zaccardelli | COO | Sell | 4,000 | $146.68 | $586,720.00 | | |
| 2/10/2015 | Roger Jeffs | CEO | Sell | 10,000 | $146.68 | $1,466,800.00 | | |
| 2/9/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $143.32 | $371,485.44 | | |
| 2/5/2015 | John Maxim Ferrari | CFO | Sell | 10,000 | $141.92 | $1,419,200.00 | | |
| 2/5/2015 | Martine A Rothblatt | CEO | Sell | 11,773 | $141.07 | $1,660,817.11 | | |
| 2/5/2015 | Paul A Mahon | EVP | Sell | 6,000 | $141.92 | $851,520.00 | | |
| 2/5/2015 | Raymond Dwek | Director | Sell | 3,000 | $140.41 | $421,230.00 | | |
| 2/3/2015 | David Zaccardelli | COO | Sell | 4,000 | $141.99 | $567,960.00 | | |
| 2/3/2015 | Roger Jeffs | CEO | Sell | 10,000 | $141.99 | $1,419,900.00 | | |
| 1/29/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $143.29 | $1,384,467.98 | | |
| 1/28/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $145.49 | $321,678.39 | | |
| 1/27/2015 | David Zaccardelli | COO | Sell | 4,000 | $147.19 | $588,760.00 | | |
| 1/27/2015 | Roger Jeffs | CEO | Sell | 10,000 | $147.19 | $1,471,900.00 | | |
| 1/26/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $145.89 | $378,146.88 | | |
| 1/22/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $146.76 | $1,742,481.48 | | |
| 1/20/2015 | David Zaccardelli | COO | Sell | 4,000 | $146.48 | $585,920.00 | | |
| 1/20/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $145.06 | $375,995.52 | | |
| 1/15/2015 | John Maxim Ferrari | CFO | Sell | 22,500 | $137.84 | $3,101,400.00 | | |
| 1/15/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $137.51 | $1,328,621.62 | | |
| 1/15/2015 | Paul A Mahon | EVP | Sell | 6,000 | $137.84 | $827,040.00 | | |
| 1/14/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $135.18 | $298,882.98 | | |
| 1/13/2015 | David Zaccardelli | COO | Sell | 3,000 | $134.71 | $404,130.00 | | |
| 1/13/2015 | Roger Jeffs | CEO | Sell | 10,000 | $134.71 | $1,347,100.00 | | |
| 1/12/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.00 | $342,144.00 | | |
| 1/8/2015 | Christopher Patusky | Director | Sell | 5,000 | $128.13 | $640,650.00 | | |
| 1/8/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $128.31 | $1,239,731.22 | | |
| 1/7/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $126.04 | $278,674.44 | | |
| 1/6/2015 | David Zaccardelli | COO | Sell | 3,000 | $124.93 | $374,790.00 | | |
| 1/6/2015 | Roger Jeffs | CEO | Sell | 7,500 | $124.93 | $936,975.00 | | |
| 1/5/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $126.88 | $328,872.96 | | |
| 1/2/2015 | Christopher Causey | Director | Sell | 3,000 | $129.25 | $387,750.00 | | |
| 1/2/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $126.53 | $1,222,532.86 | | |
| 1/2/2015 | Paul A Mahon | EVP | Sell | 6,000 | $127.73 | $766,380.00 | | |
| 12/31/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $131.35 | $290,414.85 | | |
| 12/30/2014 | Roger Jeffs | CEO | Sell | 10,000 | $130.80 | $1,308,000.00 | | |
| 12/29/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $131.75 | $341,496.00 | | |
| 12/26/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $131.85 | $1,273,934.70 | | |
| 12/24/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $130.35 | $288,203.85 | | |
| 12/23/2014 | Roger Jeffs | COO | Sell | 10,000 | $127.82 | $1,278,200.00 | | |
| 12/22/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $133.45 | $345,902.40 | | |
| 12/19/2014 | Christopher Causey | Director | Sell | 1,500 | $131.47 | $197,205.00 | | |
| 12/18/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $131.11 | $1,311,100.00 | | |
| 12/18/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $129.06 | $1,246,977.72 | | |
| 12/18/2014 | Paul A Mahon | EVP | Sell | 10,750 | $130.03 | $1,397,822.50 | | |
| 12/17/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $126.04 | $278,674.44 | | |
| 12/15/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $129.75 | $336,312.00 | | |
| 12/11/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $130.98 | $1,265,528.76 | | |
| 12/10/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $132.77 | $293,554.47 | | |
| 12/9/2014 | Roger Jeffs | COO | Sell | 10,000 | $134.80 | $1,348,000.00 | | |
| 12/8/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.34 | $343,025.28 | | |
| 12/4/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $129.05 | $1,290,500.00 | | |
| 12/4/2014 | Martine A Rothblatt | CEO | Sell | 11,873 | $131.32 | $1,559,162.36 | | |
| 12/4/2014 | Paul A Mahon | EVP | Sell | 11,000 | $129.92 | $1,429,120.00 | | |
| 12/4/2014 | Raymond Dwek | Director | Sell | 3,000 | $131.58 | $394,740.00 | | |
| 12/2/2014 | Roger Jeffs | COO | Sell | 10,000 | $133.63 | $1,336,300.00 | | |
| 12/1/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.92 | $344,528.64 | | |
| 11/28/2014 | Martine A Rothblatt | CEO | Sell | 11,873 | $132.77 | $1,576,378.21 | | |
| 11/25/2014 | Roger Jeffs | COO | Sell | 10,000 | $131.30 | $1,313,000.00 | | |
| 11/24/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $130.72 | $338,826.24 | | |
| 11/21/2014 | Roger Jeffs | COO | Sell | 10,000 | $130.15 | $1,301,500.00 | | |
| 11/20/2014 | Christopher Causey | Director | Sell | 1,500 | $127.20 | $190,800.00 | | |
| 11/20/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $129.22 | $1,292,200.00 | | |
| 11/20/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $128.86 | $1,245,045.32 | | |
| 11/20/2014 | Paul A Mahon | EVP | Sell | 11,000 | $129.02 | $1,419,220.00 | | |
| 11/19/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $128.69 | $284,533.59 | | |
| 11/18/2014 | Roger Jeffs | COO | Sell | 10,000 | $128.21 | $1,282,100.00 | | |
| 11/17/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $125.65 | $325,684.80 | | |
| 11/13/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $124.79 | $1,205,720.98 | | |
| 11/12/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $122.88 | $271,687.68 | | |
| 11/10/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $125.14 | $324,362.88 | | |
| 11/7/2014 | Christopher Patusky | Director | Sell | 5,000 | $124.49 | $622,450.00 | | |
| 11/7/2014 | Roger Jeffs | COO | Sell | 10,000 | $124.46 | $1,244,600.00 | | |
| 11/6/2014 | Christopher Causey | Director | Sell | 1,500 | $122.89 | $184,335.00 | | |
| 11/6/2014 | Martine A Rothblatt | CEO | Sell | 4,115 | $125.33 | $515,732.95 | | |
| 11/6/2014 | Paul A Mahon | EVP | Sell | 5,000 | $125.02 | $625,100.00 | | |
| 11/5/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $124.31 | $274,849.41 | | |
| 11/3/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $127.49 | $330,454.08 | | |
| 10/30/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $130.42 | $1,260,118.04 | | |
| 10/29/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $131.10 | $289,862.10 | | |
| 10/27/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.16 | $342,558.72 | | |
| 10/23/2014 | Martine A Rothblatt | CEO | Sell | 11,873 | $129.97 | $1,543,133.81 | | |
| 10/23/2014 | Paul A Mahon | EVP | Sell | 11,000 | $127.04 | $1,397,440.00 | | |
| 10/13/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $124.31 | $322,211.52 | | |
| 10/9/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $129.97 | $1,255,770.14 | | |
| 10/9/2014 | Paul A Mahon | EVP | Sell | 5,000 | $130.59 | $652,950.00 | | |
| 10/8/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $131.50 | $290,746.50 | | |
| 10/7/2014 | Roger Jeffs | COO | Sell | 35,000 | $130.14 | $4,554,900.00 | | |
| 10/6/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $129.32 | $335,197.44 | | |
| 10/3/2014 | Roger Jeffs | COO | Sell | 10,000 | $129.79 | $1,297,900.00 | | |
| 10/2/2014 | Christopher Causey | Director | Sell | 1,500 | $130.65 | $195,975.00 | | |
| 10/2/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $129.46 | $1,294,600.00 | | |
| 10/2/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $127.72 | $1,234,030.64 | | |
| 10/2/2014 | Paul A Mahon | EVP | Sell | 6,000 | $129.46 | $776,760.00 | | |
| 10/1/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $127.40 | $281,681.40 | | |
| 9/30/2014 | Roger Jeffs | COO | Sell | 20,000 | $128.65 | $2,573,000.00 | | |
| 9/25/2014 | Martine A Rothblatt | CEO | Sell | 5,547 | $134.26 | $744,740.22 | | |
| 9/25/2014 | Paul A Mahon | EVP | Sell | 5,000 | $133.77 | $668,850.00 | | |
| 9/25/2014 | Richard Giltner | Director | Sell | 20,000 | $134.94 | $2,698,800.00 | | |
| 9/23/2014 | Roger Jeffs | COO | Sell | 50,000 | $131.02 | $6,551,000.00 | | |
| 9/19/2014 | Roger Jeffs | COO | Sell | 10,000 | $129.60 | $1,296,000.00 | | |
| 9/18/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $130.93 | $1,309,300.00 | | |
| 9/18/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $127.35 | $1,230,455.70 | | |
| 9/18/2014 | Paul A Mahon | EVP | Sell | 6,000 | $130.93 | $785,580.00 | | |
| 9/17/2014 | Roger Jeffs | COO | Sell | 20,000 | $127.01 | $2,540,200.00 | | |
| 9/15/2014 | Martine A Rothblatt | CEO | Sell | 50,000 | $124.52 | $6,226,000.00 | | |
| 9/11/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $120.79 | $1,167,072.98 | | |
| 9/11/2014 | Paul A Mahon | EVP | Sell | 5,000 | $120.70 | $603,500.00 | | |
| 9/10/2014 | Martine A Rothblatt | CEO | Sell | 50,000 | $120.01 | $6,000,500.00 | | |
| 9/10/2014 | Richard Giltner | Director | Sell | 20,000 | $119.95 | $2,399,000.00 | | |
| 9/5/2014 | Roger Jeffs | COO | Sell | 10,000 | $111.29 | $1,112,900.00 | | |
| 9/4/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $112.38 | $1,123,800.00 | | |
| 9/4/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $112.87 | $1,090,549.94 | | |
| 9/4/2014 | Paul A Mahon | EVP | Sell | 6,000 | $112.38 | $674,280.00 | | |
| 9/4/2014 | Raymond Dwek | Director | Sell | 3,000 | $113.40 | $340,200.00 | | |
| 8/28/2014 | Martine A Rothblatt | CEO | Sell | 7,014 | $92.46 | $648,514.44 | | |
| 8/28/2014 | Paul A Mahon | EVP | Sell | 5,000 | $92.07 | $460,350.00 | | |
| 8/21/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $93.75 | $937,500.00 | | |
| 8/21/2014 | Martine A Rothblatt | CEO | Sell | 9,640 | $93.13 | $897,773.20 | | |
| 8/15/2014 | Christopher Causey | Director | Sell | 1,500 | $91.14 | $136,710.00 | | |
| 8/14/2014 | Martine A Rothblatt | CEO | Sell | 4,115 | $88.39 | $363,724.85 | | |
| 8/14/2014 | Paul A Mahon | EVP | Sell | 10,000 | $88.41 | $884,100.00 | | |
| 8/7/2014 | Christopher Patusky | Director | Sell | 5,000 | $88.23 | $441,150.00 | | |
| 8/7/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $86.44 | $864,400.00 | | |
| 8/7/2014 | Martine A Rothblatt | CEO | Sell | 4,115 | $88.40 | $363,766.00 | | |
| 8/1/2014 | Raymond Dwek | Director | Sell | 3,000 | $89.52 | $268,560.00 | | |
| 8/1/2014 | Roger Jeffs | COO | Sell | 10,000 | $89.88 | $898,800.00 | | |
| 7/31/2014 | Martine A Rothblatt | CEO | Sell | 3,933 | $90.95 | $357,706.35 | | |
| 7/29/2014 | Roger Jeffs | COO | Sell | 50,000 | $96.25 | $4,812,500.00 | | |
| 7/25/2014 | Roger Jeffs | COO | Sell | 10,000 | $91.54 | $915,400.00 | | |
| 7/24/2014 | Martine A Rothblatt | CEO | Sell | 9,228 | $93.15 | $859,588.20 | | |
| 7/17/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $89.74 | $897,400.00 | | |
| 7/17/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $90.87 | $348,304.71 | | |
| 7/11/2014 | Roger Jeffs | COO | Sell | 10,000 | $93.06 | $930,600.00 | | |
| 7/10/2014 | Martine A Rothblatt | CEO | Sell | 9,187 | $92.33 | $848,235.71 | | |
| 7/3/2014 | Christopher Causey | Director | Sell | 1,500 | $91.62 | $137,430.00 | | |
| 7/3/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $90.58 | $905,800.00 | | |
| 7/3/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $91.37 | $350,221.21 | | |
| 6/26/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $87.23 | $334,352.59 | | |
| 6/20/2014 | Roger Jeffs | COO | Sell | 10,000 | $87.00 | $870,000.00 | | |
| 6/19/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $87.02 | $870,200.00 | | |
| 6/19/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $85.68 | $328,411.44 | | |
| 6/19/2014 | Paul A Mahon | EVP | Sell | 2,000 | $85.67 | $171,340.00 | | |
| 6/12/2014 | Martine A Rothblatt | CEO | Sell | 9,066 | $98.22 | $890,462.52 | | |
| 6/10/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.29 | $962,900.00 | | |
| 6/9/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.32 | $963,200.00 | | |
| 6/5/2014 | Christopher Causey | Director | Sell | 1,500 | $96.48 | $144,720.00 | | |
| 6/5/2014 | Martine A Rothblatt | CEO | Sell | 9,066 | $96.46 | $874,506.36 | | |
| 6/5/2014 | Paul A Mahon | EVP | Sell | 6,000 | $96.50 | $579,000.00 | | |
| 6/3/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.00 | $950,000.00 | | |
| 5/29/2014 | Martine A Rothblatt | CEO | Sell | 9,066 | $95.27 | $863,717.82 | | |
| 5/27/2014 | Roger Jeffs | COO | Sell | 10,000 | $99.14 | $991,400.00 | | |
| 5/22/2014 | Louis Sullivan | Director | Sell | 30,000 | $101.46 | $3,043,800.00 | | |
| 5/22/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $101.35 | $918,839.10 | 140 | |
| 5/20/2014 | Roger Jeffs | COO | Sell | 10,000 | $99.91 | $999,100.00 | 1,234 | |
| 5/16/2014 | Roger Jeffs | COO | Sell | 10,000 | $100.00 | $1,000,000.00 | 1,234 | |
| 5/15/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $101.49 | $1,014,900.00 | 407 | |
| 5/15/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $100.88 | $914,578.08 | 140 | |
| 5/15/2014 | Paul Mahon | EVP | Sell | 6,000 | $100.86 | $605,160.00 | 34,832 | |
| 5/13/2014 | Roger Jeffs | COO | Sell | 10,000 | $105.53 | $1,055,300.00 | 1,234 | |
| 5/8/2014 | Christopher Patusky | Director | Sell | 5,000 | $107.17 | $535,850.00 | | |
| 5/8/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $107.83 | $977,586.78 | 140 | |
| 5/6/2014 | Roger Jeffs | COO | Sell | 10,000 | $106.50 | $1,065,000.00 | 1,234 | |
| 5/2/2014 | Roger Jeffs | COO | Sell | 10,000 | $102.00 | $1,020,000.00 | 1,234 | |
| 5/1/2014 | Christopher Causey | Director | Sell | 1,500 | $99.30 | $148,950.00 | 733 | |
| 5/1/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $102.20 | $1,022,000.00 | 407 | |
| 5/1/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $101.84 | $923,281.44 | 140 | |
| 5/1/2014 | Paul Mahon | EVP | Sell | 6,000 | $102.71 | $616,260.00 | 34,832 | |
| 4/29/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.00 | $950,000.00 | 1,234 | |
| 4/24/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $92.45 | $838,151.70 | 140 | |
| 4/22/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.00 | $960,000.00 | 1,234 | |
| 4/17/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $96.20 | $962,000.00 | 407 | |
| 4/17/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $98.48 | $892,819.68 | 140 | |
| 4/17/2014 | Paul Mahon | EVP | Sell | 6,000 | $98.37 | $590,220.00 | 34,832 | |
| 4/15/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.06 | $950,600.00 | 1,234 | |
| 4/10/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $96.18 | $871,967.88 | 140 | |
| 4/8/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.00 | $950,000.00 | 1,234 | |
| 4/4/2014 | Roger Jeffs | COO | Sell | 10,000 | $93.22 | $932,200.00 | 1,234 | |
| 4/3/2014 | Christopher Causey | Director | Sell | 1,500 | $95.67 | $143,505.00 | 733 | |
| 4/3/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $93.22 | $932,200.00 | 407 | |
| 4/3/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $93.74 | $849,846.84 | 140 | |
| 4/3/2014 | Paul Mahon | EVP | Sell | 6,000 | $93.10 | $558,600.00 | 34,832 | |
| 4/1/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.44 | $954,400.00 | 1,234 | |
| 3/27/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $93.35 | $846,311.10 | 140 | |
| 3/25/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.64 | $956,400.00 | 1,234 | |
| 3/21/2014 | Roger Jeffs | COO | Sell | 10,000 | $93.84 | $938,400.00 | 1,234 | |
| 3/20/2014 | Christopher Causey | Director | Sell | 1,500 | $96.04 | $144,060.00 | 733 | |
| 3/20/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $96.11 | $961,100.00 | 407 | |
| 3/20/2014 | Martine Rothblatt | CEO | Sell | 9,065 | $96.76 | $877,129.40 | 140 | |
| 3/20/2014 | Paul Mahon | EVP | Sell | 6,000 | $96.81 | $580,860.00 | 34,832 | |
| 3/18/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.51 | $965,100.00 | 1,234 | |
| 3/13/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $95.64 | $366,588.12 | 140 | |
| 3/7/2014 | Roger Jeffs | COO | Sell | 10,000 | $99.02 | $990,200.00 | 1,234 | |
| 3/6/2014 | Christopher Patusky | Director | Sell | 5,000 | $101.39 | $506,950.00 | | |
| 3/6/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $99.07 | $990,700.00 | 407 | |
| 3/6/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $102.77 | $393,917.41 | 140 | |
| 3/6/2014 | Paul Mahon | EVP | Sell | 6,000 | $101.93 | $611,580.00 | 34,832 | |
| 2/28/2014 | Ray Kurzweil | Director | Sell | 15,000 | $101.42 | $1,521,300.00 | | |
| 2/27/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $100.68 | $385,906.44 | 140 | |
| 2/21/2014 | Roger Jeffs | COO | Sell | 10,000 | $104.89 | $1,048,900.00 | 897 | |
| 2/20/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $103.91 | $398,287.03 | 140 | |
| 2/20/2014 | Paul Mahon | EVP | Sell | 6,000 | $104.63 | $627,780.00 | 34,490 | |
| 2/13/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $99.87 | $382,801.71 | 140 | |
| 2/7/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.61 | $966,100.00 | 897 | |
| 2/6/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $97.26 | $372,797.58 | 140 | |
| 2/6/2014 | Paul Mahon | EVP | Sell | 6,000 | $97.41 | $584,460.00 | 34,490 | |
| 2/6/2014 | Raymond Dwek | Director | Sell | 3,000 | $97.33 | $291,990.00 | | |
| 1/30/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $106.25 | $407,256.25 | 140 | |
| 1/23/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $111.78 | $428,452.74 | 140 | |
| 1/17/2014 | Roger Jeffs | COO | Sell | 10,000 | $113.03 | $1,130,300.00 | 897 | |
| 1/16/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $111.21 | $426,267.93 | 140 | |
| 1/16/2014 | Paul Mahon | EVP | Sell | 6,000 | $111.98 | $671,880.00 | 34,490 | |
| 1/9/2014 | Christopher Patusky | Director | Sell | 5,000 | $110.00 | $550,000.00 | | |
| 1/9/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $108.35 | $415,305.55 | 140 | |
| 1/3/2014 | Roger Jeffs | COO | Sell | 10,000 | $110.72 | $1,107,200.00 | 897 | |
| 1/2/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $111.54 | $427,532.82 | 140 | |
| 1/2/2014 | Paul Mahon | EVP | Sell | 6,000 | $110.78 | $664,680.00 | 34,490 | |
| 1/2/2014 | Raymond Dwek | Director | Sell | 3,000 | $111.41 | $334,230.00 | | |
| 12/31/2013 | Martine Rothblatt | CEO | Sell | 18,140 | $112.64 | $2,043,289.60 | 140 | |
| 12/30/2013 | Martine Rothblatt | CEO | Sell | 18,147 | $111.60 | $2,025,205.20 | 140 | |
| 12/27/2013 | Martine Rothblatt | CEO | Sell | 18,147 | $113.15 | $2,053,333.05 | 140 | |
| 12/26/2013 | Martine Rothblatt | CEO | Sell | 21,981 | $111.95 | $2,460,772.95 | 140 | |
| 12/24/2013 | Martine Rothblatt | CEO | Sell | 18,149 | $114.05 | $2,069,893.45 | 140 | |
| 12/23/2013 | Martine Rothblatt | CEO | Sell | 5,743 | $109.71 | $630,064.53 | 140 | |
| 12/20/2013 | Martine Rothblatt | CEO | Sell | 18,149 | $86.72 | $1,573,881.28 | 140 | |
| 12/20/2013 | Roger Jeffs | COO | Sell | 8,250 | $87.84 | $724,680.00 | 897 | |
| 12/19/2013 | Martine Rothblatt | CEO | Sell | 21,982 | $86.73 | $1,906,498.86 | 140 | |
| 12/19/2013 | Paul Mahon | EVP | Sell | 6,000 | $86.45 | $518,700.00 | 34,490 | |
| 12/18/2013 | Martine Rothblatt | CEO | Sell | 18,149 | $86.36 | $1,567,347.64 | 140 | |
| 12/17/2013 | Martine Rothblatt | CEO | Sell | 12,251 | $86.49 | $1,059,588.99 | 140 | |
| 12/6/2013 | Roger Jeffs | COO | Sell | 10,000 | $90.97 | $909,700.00 | 19,760 | |
| 12/5/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $89.79 | $344,165.07 | 140 | |
| 12/5/2013 | Paul Mahon | EVP | Sell | 6,000 | $89.18 | $535,080.00 | 34,490 | |
| 12/5/2013 | Raymond Dwek | Director | Sell | 3,000 | $90.13 | $270,390.00 | | |
| 11/21/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $92.49 | $354,514.17 | 140 | |
| 11/21/2013 | Paul Mahon | EVP | Sell | 6,000 | $92.47 | $554,820.00 | 34,490 | |
| 11/15/2013 | Roger Jeffs | COO | Sell | 10,000 | $94.00 | $940,000.00 | 19,760 | |
| 11/14/2013 | Christopher Patusky | Director | Sell | 5,500 | $91.65 | $504,075.00 | | |
| 11/14/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $91.60 | $351,102.80 | 140 | |
| 11/7/2013 | Christopher Patusky | Director | Sell | 3,500 | $90.51 | $316,785.00 | | |
| 11/7/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $89.47 | $342,938.51 | 140 | |
| 11/7/2013 | Paul Mahon | EVP | Sell | 6,000 | $89.60 | $537,600.00 | 34,490 | |
| 11/1/2013 | Raymond Dwek | Director | Sell | 3,000 | $89.18 | $267,540.00 | | |
| 11/1/2013 | Roger Jeffs | COO | Sell | 10,000 | $90.34 | $903,400.00 | | |
| 10/31/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $86.89 | $333,049.37 | | |
| 10/24/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $83.77 | $321,090.41 | | |
| 10/18/2013 | Roger Jeffs | COO | Sell | 10,000 | $82.47 | $824,700.00 | | |
| 10/17/2013 | John Maxim Ferrari | CFO | Sell | 2,750 | $82.01 | $225,527.50 | | |
| 10/17/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $81.84 | $313,692.72 | | |
| 10/17/2013 | Paul A Mahon | EVP | Sell | 6,000 | $81.79 | $490,740.00 | | |
| 10/10/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $82.58 | $316,529.14 | 140 | |
| 10/4/2013 | Roger Jeffs | COO | Sell | 10,000 | $85.48 | $854,800.00 | | |
| 10/3/2013 | Christopher Causey | Director | Sell | 1,500 | $83.15 | $124,725.00 | | |
| 10/3/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $84.67 | $381,015.00 | | |
| 10/3/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $84.20 | $322,738.60 | | |
| 10/3/2013 | Paul A Mahon | EVP | Sell | 6,000 | $84.38 | $506,280.00 | | |
| 9/26/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $78.41 | $300,545.53 | 140 | |
| 9/20/2013 | Roger Jeffs | COO | Sell | 10,000 | $77.86 | $778,600.00 | 19,760 | |
| 9/19/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $78.67 | $354,015.00 | 407 | |
| 9/19/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $78.12 | $299,433.96 | 140 | |
| 9/19/2013 | Paul Mahon | EVP | Sell | 6,000 | $78.02 | $468,120.00 | 34,490 | |
| 9/12/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $76.98 | $295,064.34 | | |
| 9/6/2013 | Roger Jeffs | COO | Sell | 10,000 | $73.67 | $736,700.00 | | |
| 9/5/2013 | Christopher Causey | Director | Sell | 1,500 | $73.11 | $109,665.00 | | |
| 9/5/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $74.17 | $333,765.00 | | |
| 9/5/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $73.63 | $282,223.79 | | |
| 9/5/2013 | Paul A Mahon | EVP | Sell | 6,000 | $73.29 | $439,740.00 | | |
| 8/29/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $72.76 | $278,889.08 | 140 | |
| 8/22/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $72.06 | $276,205.98 | 140 | |
| 8/16/2013 | Roger Jeffs | COO | Sell | 10,000 | $71.21 | $712,100.00 | 19,760 | |
| 8/15/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $71.14 | $320,130.00 | | |
| 8/15/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $71.58 | $274,366.14 | 140 | |
| 8/15/2013 | Paul Mahon | EVP | Sell | 6,000 | $71.34 | $428,040.00 | 34,490 | |
| 8/8/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $73.11 | $280,230.63 | 140 | |
| 8/2/2013 | Roger Jeffs | COO | Sell | 10,000 | $76.69 | $766,900.00 | | |
| 8/1/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $75.87 | $341,415.00 | | |
| 8/1/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $75.97 | $291,193.01 | | |
| 8/1/2013 | Paul A Mahon | EVP | Sell | 6,000 | $75.91 | $455,460.00 | | |
| 8/1/2013 | Raymond Dwek | Director | Sell | 3,000 | $75.94 | $227,820.00 | | |
| 7/31/2013 | R Paul Gray | Director | Sell | 7,500 | $74.93 | $561,975.00 | | |
| 7/25/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $71.45 | $273,867.85 | | |
| 7/19/2013 | Roger Jeffs | COO | Sell | 10,000 | $70.00 | $700,000.00 | | |
| 7/18/2013 | John Maxim Ferrari | CFO | Sell | 9,000 | $69.85 | $628,650.00 | | |
| 7/18/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $68.96 | $264,323.68 | | |
| 7/18/2013 | Paul A Mahon | EVP | Sell | 6,000 | $69.15 | $414,900.00 | | |
| 7/11/2013 | Martine A Rothblatt | CEO | Sell | 3,837 | $67.94 | $260,685.78 | | |
| 7/5/2013 | Christopher Causey | Director | Sell | 1,500 | $66.33 | $99,495.00 | | |
| 7/5/2013 | Martine A Rothblatt | CEO | Sell | 3,863 | $67.28 | $259,902.64 | | |
| 7/5/2013 | Paul A Mahon | EVP | Sell | 6,000 | $67.04 | $402,240.00 | | |
| 7/5/2013 | Roger Jeffs | COO | Sell | 10,000 | $67.21 | $672,100.00 | | |
| 6/21/2013 | Roger Jeffs | COO | Sell | 10,000 | $63.34 | $633,400.00 | | |
| 6/20/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $63.22 | $284,490.00 | | |
| 6/20/2013 | Paul A Mahon | EVP | Sell | 6,000 | $63.29 | $379,740.00 | | |
| 6/7/2013 | Roger Jeffs | COO | Sell | 10,000 | $67.00 | $670,000.00 | | |
| 6/6/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $64.84 | $291,780.00 | | |
| 6/6/2013 | Paul A Mahon | EVP | Sell | 6,000 | $63.84 | $383,040.00 | | |
| 6/6/2013 | Raymond Dwek | Director | Sell | 3,000 | $63.77 | $191,310.00 | | |
| 5/17/2013 | Roger Jeffs | COO | Sell | 10,000 | $69.17 | $691,700.00 | | |
| 5/16/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $68.48 | $308,160.00 | | |
| 5/16/2013 | Paul A Mahon | EVP | Sell | 6,000 | $68.05 | $408,300.00 | | |
| 5/2/2013 | Paul A Mahon | EVP | Sell | 6,000 | $67.15 | $402,900.00 | | |
| 5/2/2013 | Raymond Dwek | Director | Sell | 3,000 | $66.75 | $200,250.00 | | |
| 4/11/2013 | Raymond Dwek | Director | Sell | 9,000 | $61.35 | $552,150.00 | | |
| 1/17/2013 | Paul A Mahon | EVP | Sell | 5,749 | $52.20 | $300,097.80 | | |
| 12/28/2012 | Martine A Rothblatt | CEO | Buy | 4,167 | $52.40 | $218,350.80 | | |
| 12/26/2012 | Martine A Rothblatt | CEO | Buy | 6,000 | $52.40 | $314,400.00 | | |
| 12/21/2012 | Martine A Rothblatt | CEO | Buy | 9,000 | $51.85 | $466,650.00 | | |
| 11/26/2012 | Christopher Causey | Director | Sell | 1,500 | $53.33 | $79,995.00 | | |
| 10/4/2012 | Christopher Causey | Director | Sell | 1,500 | $58.33 | $87,495.00 | | |
| 10/4/2012 | John Maxim Ferrari | CFO | Sell | 1,550 | $58.00 | $89,900.00 | | |
| 10/4/2012 | Paul A Mahon | EVP | Sell | 6,000 | $38.00 | $228,000.00 | | |
| 9/6/2012 | Christopher Causey | Director | Sell | 1,500 | $55.94 | $83,910.00 | | |
| 9/5/2012 | Christopher Patusky | Director | Sell | 2,000 | $55.47 | $110,940.00 | | |
(Data available from 1/1/2013 forward)
United Therapeutics (NASDAQ UTHR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Commit To Purchase United Therapeutics Corp At $100, Earn 12.5% Annualized Using Options
www.nasdaq.com - April 20 at 5:35 PM |
 | United Therapeutics (UTHR) to Release Earnings on Tuesday
www.americanbankingnews.com - April 17 at 3:46 AM |
| United Therapeutics Co. (UTHR) CEO Martine A. Rothblatt Sells 21,513 Shares
www.americanbankingnews.com - April 11 at 4:15 PM |
| Zacks: Analysts Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $397.50 Million
www.americanbankingnews.com - April 10 at 2:01 AM |
| $3.64 EPS Expected for United Therapeutics Co. (UTHR) This Quarter
www.americanbankingnews.com - April 8 at 11:16 PM |
| Martine A. Rothblatt Sells 21,512 Shares of United Therapeutics Co. (UTHR) Stock
www.americanbankingnews.com - April 6 at 4:17 PM |
 | United Therapeutics buys two D.C. buildings for $6.5M for 'potential future expansion'
www.bizjournals.com - April 5 at 5:31 PM |
| Cowen Reaffirms Hold Rating for United Therapeutics (UTHR)
www.americanbankingnews.com - April 4 at 5:52 PM |
| United Therapeutics Co. (UTHR) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 5:34 PM |
| Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 22,059 Shares of Stock
www.americanbankingnews.com - April 4 at 4:19 PM |
 | UPDATE: Credit Suisse Upgrades United Therapeutics Corp. (UTHR) to Neutral
www.streetinsider.com - April 4 at 8:01 AM |
 | United Therapeutics Has Limited Downside Below $95 Level, Credit Suisse Says In Upgrade
www.msn.com - April 3 at 5:48 PM |
| United Therapeutics (UTHR) Upgraded by Credit Suisse Group to "Neutral"
www.americanbankingnews.com - April 3 at 11:08 AM |
 | How Did United Therapeutics Perform in 4Q17 and Fiscal 2017?
finance.yahoo.com - April 3 at 8:04 AM |
| How United Therapeutics’ Adcirca and Orenitram Performed in 2017
finance.yahoo.com - April 3 at 8:04 AM |
| Is United Therapeutics Corporation (NASDAQ:UTHR) A Financially Strong Company?
finance.yahoo.com - March 30 at 5:46 PM |
| Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 43,024 Shares of Stock
www.americanbankingnews.com - March 30 at 4:14 PM |
| United Therapeutics (UTHR) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - March 25 at 12:54 AM |
| United Therapeutics (UTHR) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM |
| Why Is United Therapeutics (UTHR) Down 10.7% Since Its Last Earnings Report? - Nasdaq
www.nasdaq.com - March 24 at 8:35 AM |
| Why Is United Therapeutics (UTHR) Down 10.7% Since Its Last Earnings Report?
finance.yahoo.com - March 23 at 6:01 PM |
| Martine A. Rothblatt Sells 1,100 Shares of United Therapeutics Co. (UTHR) Stock
www.americanbankingnews.com - March 23 at 4:34 PM |
| Zacks: Brokerages Expect United Therapeutics Co. (UTHR) to Announce $3.64 EPS
www.americanbankingnews.com - March 22 at 11:08 PM |
| Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 301 Shares of Stock
www.americanbankingnews.com - March 21 at 4:08 PM |
| Validea Benjamin Graham Strategy Daily Upgrade Report - 3/21 ... - Nasdaq
www.nasdaq.com - March 21 at 8:16 AM |
| Investor Expectations to Drive Momentum within JELD-WEN Holding, Nathan's Famous, Aerie Pharmaceuticals, RBC Bearings, Malibu Boats, and United Therapeutics — Discovering Underlying Factors of Influence
finance.yahoo.com - March 21 at 8:16 AM |
| Should Value Investors Pick United Therapeutics (UTHR) Stock? - Nasdaq
www.nasdaq.com - March 20 at 8:05 AM |
| Should Value Investors Pick United Therapeutics (UTHR) Stock?
finance.yahoo.com - March 19 at 5:31 PM |
| Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 43,025 Shares of Stock
www.americanbankingnews.com - March 16 at 7:14 PM |
 | United Therapeutics (UTHR) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 14 at 7:27 PM |
| Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 21,512 Shares of Stock
www.americanbankingnews.com - March 14 at 7:11 PM |
 | United Therapeutics Corporation To Present At Oppenheimer 28th Annual Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 14 at 8:05 AM |
| United Therapeutics Corporation To Present At Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 8:05 AM |
| United Therapeutics Co. (UTHR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 6:12 PM |
| United Therapeutics tries to reverse downtrend, up 6%
seekingalpha.com - March 8 at 7:03 PM |
| United Therapeutics Corporation To Present At Cowen And Company 38th Annual Health Care Conference - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:00 AM |
| United Therapeutics Corporation To Present At Cowen And Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 8:00 AM |
| United Therapeutics Co. (UTHR) Expected to Announce Quarterly Sales of $397.50 Million
www.americanbankingnews.com - March 7 at 2:48 AM |
| United Therapeutics Co. (UTHR) Shares Bought by University of Notre Dame DU Lac
www.americanbankingnews.com - March 6 at 12:07 PM |
| United Therapeutics Co. (UTHR) Shares Sold by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 5 at 9:42 AM |
| The Manufacturers Life Insurance Company Has $10.61 Million Holdings in United Therapeutics Co. (UTHR)
www.americanbankingnews.com - March 3 at 8:34 AM |
| Standard Life Aberdeen plc Trims Stake in United Therapeutics Co. (UTHR)
www.americanbankingnews.com - March 2 at 8:26 PM |
| Q3 2018 EPS Estimates for United Therapeutics Co. Boosted by Wedbush (UTHR)
www.americanbankingnews.com - March 2 at 11:32 AM |
| Blog Exposure - Cipher Pharma Acquired Canadian Rights to Synergy Pharma’s FDA-Approved TRULANCE(R)
finance.yahoo.com - March 2 at 8:00 AM |
| State of Wisconsin Investment Board Has $6.80 Million Position in United Therapeutics Co. (UTHR)
www.americanbankingnews.com - March 1 at 6:04 PM |
| Burney Co. Purchases 3,499 Shares of United Therapeutics Co. (UTHR)
www.americanbankingnews.com - March 1 at 5:26 AM |
| 13,713 Shares in United Therapeutics Co. (UTHR) Purchased by Brandes Investment Partners LP
www.americanbankingnews.com - March 1 at 5:18 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of United Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - February 28 at 8:01 AM |
| Rhumbline Advisers Sells 1,489 Shares of United Therapeutics Co. (UTHR)
www.americanbankingnews.com - February 28 at 7:52 AM |
| United Therapeutics Becomes Oversold (UTHR) - Nasdaq
www.nasdaq.com - February 27 at 8:00 AM |
United Therapeutics (NASDAQ:UTHR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
United Therapeutics (NASDAQ:UTHR) Income Statement, Balance Sheet and Cash Flow Statement
United Therapeutics (NASDAQ UTHR) Stock Chart for Monday, April, 23, 2018
Loading chart…
